Have you been diagnosed with non-small cell lung cancer? Have you already been treated with an anti PDL-1 therapy and chemotherapy? If so, you may be able to take part in a research study looking to compare the safety and effectiveness of the investigational drug RMC-6236 to docetaxel.

We're doing this study to understand how a type of genetic material called DNA in the blood changes in people with a specific type of cancer that has spread to only a few places in the body. By looking at how this DNA behaves before and after cancer treatment, including radiation, we aim to learn more about how the cancer responds. To do this, we'll collect blood and tumor samples from you to analyze what's happening. This could help in better understanding and improving cancer treatments for others in the future.

Have you been diagnosed with Leukemia? Do you have a functioning kidney, liver, and cardiac organ? If so, you may be able to participate in a study on a new drug called Ziftomenib. We want to find out if it hooking their interest enough to click on the link to is safe for people with Leukemia. Compensation provided.

We're looking for people with bladder cancer to join a study on a new radiation treatment. If you have bladder cancer, this study will tests if receiving higher doses of radiation in a shorter time, along with chemotherapy, works as well as standard treatments. Participating may help you avoid surgery to remove your bladder. It may also mean you finish treatment faster, which might fit better with your needs. Overall, by joining the study you can contribute to improving future bladder cancer care for you and others.

The purpose of this study is to see if etentamig is safe and to identify the optimal etentamig dose when combined with daratumumab in participants with Newly Diagnosed Multiple Myeloma (NDMM) who are not eligible for transplant.

Are you 18 years or older and diagnosed with HER2+, clinical stage T1c-T3 (or Tx) and nodal stage N0-N1 breast cancer and prior to surgery did you received chemotherapy in combination with Trastuzumab for a minimum of 12 weeks? If so, you may be eligible for a research study evaluating the effectiveness of 6 months of HER2-targeted medications (trastuzumab with or without pertuzumab) versus 12 months of HER2-targeted medications at reducing the risk of breast cancer coming back or death in patients.

We're trying to find out if a special gel is safe and easy for people with cervical cancer to use. This is for those who are also getting chemotherapy and radiation. We want to see if the gel does its job well, is quick to use, and helps keep healthy tissues safe.

You are being asked to take part in this study because you have triple negative (TN) breast cancer that has spread to your lymph nodes. You are also planning to get chemo-immunotherapy treatment before surgery. Radiation therapy (RT) has been shown to improve the body's immune response against tumors when it is given with a drug called pembrolizumab. The purpose of this study is to find the best and safest dose of radiation (low or high) when given with pembrolizumab. Radiation is measured in Gy (pronounced "gray"). You will be randomly assigned (like flipping a coin) to receive either a low dose RT boost (9 Gy) or a high dose RT boost (24 Gy). The RT will be given with one dose of pembrolizumab. This is a hybrid decentralized study where some if not all assessments may be performed close to your home.

Radiation treatment for head and neck cancer can often cause a very dry mouth. This dryness can last for a long time, even after the treatment ends. In our study, we want to see if changing where the radiation is aimed can help with this dryness. If you join, you'll fill out some simple questionnaires and give saliva samples. We'll also check in with you for about a year after your treatment to see how you're doing.

We're doing this study to explore how a device called TheraBionic affects people with liver cancer and their condition. This device uses special frequencies to target cancer cells and is being tested for treating advanced liver cancer.